Compare WFRD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFRD | PTCT |
|---|---|---|
| Founded | 1941 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | N/A | 2013 |
| Metric | WFRD | PTCT |
|---|---|---|
| Price | $103.41 | $70.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | ★ $94.33 | $76.28 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 5.93 | ★ 8.94 |
| Revenue | ★ $4,918,000,000.00 | $1,779,150,000.00 |
| Revenue This Year | N/A | $132.16 |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | $17.47 | ★ $7.93 |
| Revenue Growth | N/A | ★ 97.54 |
| 52 Week Low | $36.74 | $35.95 |
| 52 Week High | $106.41 | $87.50 |
| Indicator | WFRD | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 70.02 | 36.25 |
| Support Level | $90.23 | $71.35 |
| Resistance Level | $106.38 | $76.99 |
| Average True Range (ATR) | 3.58 | 2.84 |
| MACD | 0.79 | -0.39 |
| Stochastic Oscillator | 82.70 | 11.88 |
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.